Disease or Syndrome – Page 10

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

1 month ago talkbio0Tagged Biotechnology, Cardiospermum grandiflorum, Cell Therapy, Collaboration termination, Diabetes, Heart failure, HS-001, Maziar Mike Doustdar, Nordisk, Obesity, strategic restructuring

Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology

Star Therapeutics Raises $125M as Bleeding Disorder Therapy Enters Phase III

1 month ago talkbio0Tagged Antibody Therapy, Blood Coagulation Disorders, Infrequent, Phase 3 Clinical Trials, Series D financing, Star Therapeutics, VGA039

Star Therapeutics; Series D financing; bleeding disorders; VGA039; Phase III clinical trial; biotech funding; rare diseases; antibody therapy

Metsera’s New Obesity Data Raises Efficacy Profile, Key Side Effect Questions for Pfizer After Acquisition

1 month ago talkbio0Tagged aspects of adverse effects, Effectiveness, Glucagon-Like Peptide 1, MET-097i, Metsera, Obesity, Pfizer, Pfizer acquisition, Phase 2 trial, Weight Loss

Metsera; Pfizer; obesity drug; MET-097i; GLP-1; side effects; efficacy; Phase 2 trial; weight loss; Pfizer acquisition

Barinthus Biotherapeutics Announces Reverse Merger with Clywedog Therapeutics to Form New Metabolic Disease-Focused Company

1 month ago talkbio0Tagged Autoimmune Diseases, Barinthus, biotherapeutics, Board Composition, Clywedog Therapeutics, Delaware merger, lock-up, Menstruation, Metabolic Diseases, reverse merger, Scheme of Arrangement, Shareholder Ownership Structure, Topco, UK

Barinthus Biotherapeutics; Reverse Merger; Clywedog Therapeutics; Metabolic Diseases; Autoimmune Diseases; Topco; Shareholder Ownership Structure; UK Scheme of Arrangement; Delaware Merger; Self-Tender Offer; Lock-Up Period; Board Composition

Enanta Presses Ahead with RSV Drug Zelicapavir Despite Missing Primary Endpoint in Phase IIb Trial

1 month ago talkbio0Tagged Clinical Trials, Congestive heart failure, COPD, development aspects, Elderly (population group), Enanta, Hospitalization, Neoplasm Metastasis, Phase II B Trial, primary endpoint, rates, Respiratory syncytial virus, United States Food and Drug Administration, Zelicapavir

Enanta Pharmaceuticals; RSV; zelicapavir; Phase IIb trial; primary endpoint miss; secondary endpoints; clinical trials; FDA Fast Track; elderly; COPD; congestive heart failure; hospitalization rates; future development

MoonLake shares crash after mixed results in pivotal hidradenitis suppurativa studies

1 month ago talkbio0Tagged Bimzelx, Clinical Trials, Cosentyx, drug approval outlook, drug market, Hidradenitis Suppurativa, inhibitors, Interleukin-17, MoonLake Immunotherapeutics, Placebos, Response process, sonelokimab

MoonLake Immunotherapeutics; Sonelokimab; hidradenitis suppurativa; Phase 3 trial; clinical trial results; biotech shares; placebo response; drug approval outlook; IL-17 inhibitors; Bimzelx; Cosentyx; drug market potential

Rezon Bio Launches Two State-of-the-Art CDMO Facilities for Biologics in Europe

1 month ago talkbio0Tagged Biological Factors, Biosimilars, CDMO, Contract agreement, Digital innovation, Europe, Gdańsk, Guanosine Monophosphate, Manufacturing, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, Rezon Bio, United States Food and Drug Administration, Warsaw-Duchnice

Rezon Bio; biologics; CDMO; contract manufacturing; Gdańsk; Warsaw-Duchnice; Europe; digital innovation; GMP manufacturing; biosimilars; EMA; FDA

New Confirmatory Study Suggests Progress in Applied Therapeutics–FDA Alignment for Rare Disease Drug

1 month ago talkbio0Tagged Apply, Clinical Trials, CMT-SORD, confirmatory study, Govorestat, Infrequent, regulatory alignment, United States Food and Drug Administration

Applied Therapeutics; govorestat; CMT-SORD; rare disease; FDA; confirmatory study; clinical trial; regulatory alignment

Sanofi Expands $35 Insulin Program to All U.S. Patients Nationwide

1 month ago talkbio0Tagged Affordability, Diabetes, Insulin, Insurance, Medicare, monthly, Programs - Publication Format, sanofi, United States

Sanofi; Insulin; $35 monthly program; Insulins Valyou Savings Program; diabetes; insurance coverage; Medicare; affordability; United States

Thyme Care Raises $97 Million Series D to Drive AI-Powered Oncology Care at $1B Valuation

1 month ago talkbio0Tagged Artificial Intelligence, cancer care, Healthcare technology, oncology ecosystem, orchestration, patient navigation, Series D, strategic investors, Thyme Care, unicorn startup, Value-Based Care

Thyme Care; cancer care; Series D funding; AI orchestration; oncology ecosystem; value-based care; patient navigation; strategic investors; unicorn startup; healthcare technology